Ann: Market Update - Executing Towards Profitability in Oncology, page-114

@Twjaxon
Yes,
still working on HFD and Renal, potentially the only tool to accurately measure fluid volume to be removed, scales going the way of the tape measure.



2022 annual report.

Below trial finished June/July 2023.



Q3 23


The 2023 annual report is out soon and will report on all activities including Renal and where they are at re observational study and will indicate 2024 focus.
I don't have an opinion. The board decides direction. Correction, I just have an opinion on performance.
I do note when saying "fully focused on Oncology" they mean "oncology and other activities".

@Steini
Who benefits from a low SP and who does from a high SP. Read into that what you will. Steini likes to benefit from low SP Opportunity to buy at lower prices i.e., lower than resistance levels in the 0.20. Also agree profit taking on light volume care of CR. Sell down from news hype, typical.
I did acquire some more at 0.17 when that line got cleared on the 28th and given the opportunity will get more if goes lower. SMSF.

@sundowner1234

Yes, we would like to see them buy more, but please note there may be governance issue that would not allow to purchase at this time. I.e., major contract announcement. We will only know closer to the voting date. No news, no buying, no vote might be the play book. Only IPD knows the timing of rabbit pulls.

Kind regards
Acclivity.